Rapidemic
Rapidemic is dedicated to revolutionizing molecular diagnostics by providing fast, accurate, and decentralized testing solutions for infectious diseases like STIs. Their mission is to create a world where anyone can access quality diagnostics anytime and anywhere, improving patient care and public health through innovative, user-friendly technology.
Industries
Nr. of Employees
small (1-50)
Products
Rapid multiplex molecular STI test
A compact, equipment-free molecular diagnostic test designed to detect multiple STI targets (demonstrated for chlamydia and gonorrhea) with lab-grade sensitivity and specificity and result reporting in under 15 minutes.
Rapid multiplex molecular STI test
A compact, equipment-free molecular diagnostic test designed to detect multiple STI targets (demonstrated for chlamydia and gonorrhea) with lab-grade sensitivity and specificity and result reporting in under 15 minutes.
Services
Registration-based program to provide launch updates and opportunities for distribution or exclusive partnerships to healthcare providers, distributors, and pharmacies.
Support for integrating rapid decentralized molecular testing into clinic workflows to enable single-visit diagnosis and immediate treatment decisions.
Registration-based program to provide launch updates and opportunities for distribution or exclusive partnerships to healthcare providers, distributors, and pharmacies.
Support for integrating rapid decentralized molecular testing into clinic workflows to enable single-visit diagnosis and immediate treatment decisions.
Expertise Areas
- Decentralized molecular diagnostics
- Point-of-care testing
- Sexually transmitted infection (STI) diagnostics
- Assay development and multiplexing
Key Technologies
- Nucleic acid amplification
- Multiplex molecular assays
- Integrated sample-to-answer detection
- Portable point-of-care diagnostic platforms
News & Updates
Rapidemic collaborates with Maastricht UMC+ to advance diagnostics.
The company secures funding to support its innovative diagnostic solutions.
The company presents scientific data at the European Meeting on Molecular Diagnostics.
Recognition for the company's innovative work in diagnostics.
Rapidemic collaborates with Maastricht UMC+ to advance diagnostics.
The company secures funding to support its innovative diagnostic solutions.
The company presents scientific data at the European Meeting on Molecular Diagnostics.
Recognition for the company's innovative work in diagnostics.